Spring Creek Capital’s Medifast MED Stock Holding History

Spring Creek Capital’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,361	Closed	-$378K	–	415
2018 Q2	$378K	Buy	+2,361	New	+$302K	0.04%	531

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Spring Creek Capital's MED Position: Q3 2018 in Review

Spring Creek Capital sold out of Medifast (MED) in Q3 2018, closing a stake of 2,361 shares — an estimated $378K sold.

Spring Creek Capital first reported a position in MED in Q2 2018 and held it in 1 quarter. The position peaked at $378K in Q2 2018. 266 funds tracked by Wall St. Rank hold MED as of Q3 2018.

Spring Creek Capital reported no remaining Medifast position as of Q3 2018 after selling out during the quarter.
Spring Creek Capital sold 2,361 Medifast shares in Q3 2018, an estimated $378K.
Spring Creek Capital first reported a position in Medifast in Q2 2018 and held it in 1 quarter.
Spring Creek Capital's Medifast position peaked at $378K in Q2 2018.
266 funds tracked by Wall St. Rank held Medifast as of Q3 2018.

Based on Spring Creek Capital's 13F filing for Q3 2018, filed 13 Nov 2018.